ALNY logo

Alnylam Pharmaceuticals (ALNY) Cash From Financing

Annual CFF

$294.16 M
+$122.03 M+70.89%

December 31, 2024

Summary

Performance

1-Year Change

+70.89%

3-Year Change

-76.41%

5-Year Change

-64.27%

15-Year Change

-73.85%

ALNY Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

95.28%
ALNY annual cash flow from financing activities is higher than 95.28% of companies in Healthcare sector

High & Low

All-time High

$1.25 B
ALNY annual cash flow from financing activities is currently -76.41% below its historical high of $1.25 billion

3-Year Low

$172.13 M
ALNY annual cash flow from financing activities is currently +70.89% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
ALNY previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
ALNY next annual earnings announcement has not yet been scheduled

OtherALNYcash flowmetrics:

Annual CFI

-$116.84 M
ALNY annual cash flow from investing activities is -$116.84 million

Annual CFO

-$8.31 M
ALNY annual cash flow from operations is -$8.31 million

Annual FCF

-$42.59 M
ALNY annual free cash flow is -$42.59 million

Annual CAPEX

$34.28 M
ALNY annual capital expenditures is $34.28 million

Quarterly CFF

$31.00 M
-$71.76 M-69.83%

December 31, 2024

Summary

Performance

3-Month Change

-69.83%

1-Year Change

-20.98%

3-Year Change

-20.98%

5-Year Change

-20.98%

ALNY Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

91.86%
ALNY quarterly cash flow from financing activities is higher than 91.86% of companies in Healthcare sector

High & Low

All-time High

$718.88 M
ALNY quarterly cash flow from financing activities is currently -95.69% below its historical high of $718.88 million

3-Year Low

$28.91 M
ALNY quarterly cash flow from financing activities is currently +7.22% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
ALNY previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 2, 2025
ALNY next earnings announcement is scheduled for May 2, 2025

OtherALNYcash flowmetrics:

Quarterly CFI

-$52.91 M
ALNY quarterly cash flow from investing activities is -$52.91 million

Quarterly CFO

-$94.66 M
ALNY quarterly cash flow from operations is -$94.66 million

Quarterly FCF

-$103.76 M
ALNY quarterly free cash flow is -$103.76 million

Quarterly CAPEX

$9.09 M
ALNY quarterly capital expenditures is $9.09 million

TTM CFF

$294.16 M
-$8.23 M-2.72%

December 31, 2024

Summary

Performance

3-Month Change

-2.72%

1-Year Change

+70.89%

3-Year Change

+70.89%

5-Year Change

+70.89%

ALNY TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

93.26%
ALNY TTM cash flow from financing activities is higher than 93.26% of companies in Healthcare sector

High & Low

All-time High

$1.25 B
ALNY TTM cash flow from financing activities is currently -76.41% below its historical high of $1.25 billion

3-Year Low

$154.67 M
ALNY TTM cash flow from financing activities is currently +90.18% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
ALNY previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 2, 2025
ALNY next earnings announcement is scheduled for May 2, 2025

OtherALNYcash flowmetrics:

TTM CFI

-$116.84 M
ALNY TTM cash flow from investing activities is -$116.84 million

TTM CFO

-$8.31 M
ALNY TTM cash flow from operations is -$8.31 million

TTM FCF

-$42.59 M
ALNY TTM free cash flow is -$42.59 million

TTM CAPEX

$34.28 M
ALNY TTM capital expenditures is $34.28 million

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

ALNY Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+70.9%-21.0%+70.9%
3 y3 years-76.4%-21.0%+70.9%
5 y5 years-64.3%-21.0%+70.9%

ALNY Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-76.4%+70.9%-89.6%+7.2%-76.4%+90.2%
5 y5-year-76.4%+70.9%-95.5%+7.2%-76.4%+90.2%
alltimeall time-76.4%>+9999.0%-95.7%+249.8%-76.4%>+9999.0%

Alnylam Pharmaceuticals Cash From Financing History

DateAnnualQuarterlyTTM
Dec 2024
$294.16 M(+70.9%)
$31.00 M(-69.8%)
$294.16 M(-2.7%)
Sep 2024
-
$102.75 M(-21.9%)
$302.39 M(+29.9%)
Jun 2024
-
$131.50 M(+354.8%)
$232.77 M(+50.5%)
Mar 2024
-
$28.91 M(-26.3%)
$154.67 M(-10.1%)
Dec 2023
$172.13 M(-59.6%)
$39.23 M(+18.4%)
$172.13 M(-12.3%)
Sep 2023
-
$33.14 M(-37.9%)
$196.34 M(-57.3%)
Jun 2023
-
$53.39 M(+15.1%)
$460.23 M(+5.3%)
Mar 2023
-
$46.37 M(-26.9%)
$437.17 M(+2.7%)
Dec 2022
$425.75 M(-65.9%)
$63.44 M(-78.6%)
$425.75 M(-35.0%)
Sep 2022
-
$297.02 M(+879.1%)
$654.61 M(-29.7%)
Jun 2022
-
$30.34 M(-13.2%)
$931.42 M(-24.3%)
Mar 2022
-
$34.96 M(-88.0%)
$1.23 B(-1.3%)
Dec 2021
$1.25 B(+25.3%)
$292.29 M(-49.1%)
$1.25 B(+6.3%)
Sep 2021
-
$573.84 M(+74.0%)
$1.17 B(+85.2%)
Jun 2021
-
$329.81 M(+544.5%)
$633.09 M(-36.2%)
Mar 2021
-
$51.18 M(-76.5%)
$992.29 M(-0.3%)
Dec 2020
$994.98 M(+20.9%)
$217.95 M(+538.3%)
$994.98 M(+21.7%)
Sep 2020
-
$34.15 M(-95.0%)
$817.37 M(+7.2%)
Jun 2020
-
$689.01 M(+1179.1%)
$762.52 M(+56.9%)
Mar 2020
-
$53.87 M(+33.5%)
$486.12 M(-40.9%)
Dec 2019
$823.18 M(+1157.3%)
$40.34 M(-294.9%)
$823.18 M(+4.4%)
Sep 2019
-
-$20.70 M(-105.0%)
$788.22 M(-4.1%)
Jun 2019
-
$412.61 M(+5.5%)
$821.91 M(+98.1%)
Mar 2019
-
$390.93 M(+7169.1%)
$414.88 M(+533.7%)
Dec 2018
$65.47 M(-94.2%)
$5.38 M(-58.6%)
$65.47 M(-91.5%)
Sep 2018
-
$12.99 M(+132.7%)
$767.04 M(-2.0%)
Jun 2018
-
$5.58 M(-86.6%)
$782.97 M(-32.7%)
Mar 2018
-
$41.52 M(-94.1%)
$1.16 B(+3.4%)
Dec 2017
$1.12 B(+532.6%)
$706.95 M(+2344.9%)
$1.12 B(+167.2%)
Sep 2017
-
$28.91 M(-92.5%)
$421.02 M(+6.2%)
Jun 2017
-
$386.31 M(>+9900.0%)
$396.46 M(+141.0%)
Mar 2017
-
$2.72 M(-11.9%)
$164.48 M(-7.5%)
Dec 2016
$177.83 M(-71.1%)
$3.08 M(-29.1%)
$177.83 M(-1.9%)
Sep 2016
-
$4.35 M(-97.2%)
$181.22 M(+0.4%)
Jun 2016
-
$154.34 M(+860.6%)
$180.52 M(+442.8%)
Mar 2016
-
$16.07 M(+148.4%)
$33.26 M(-94.6%)
Dec 2015
$616.18 M(-16.3%)
$6.47 M(+77.2%)
$616.18 M(-0.2%)
Sep 2015
-
$3.65 M(-48.4%)
$617.37 M(-0.2%)
Jun 2015
-
$7.07 M(-98.8%)
$618.51 M(+0.3%)
Mar 2015
-
$598.98 M(+7721.7%)
$616.57 M(-16.3%)
Dec 2014
$736.47 M
$7.66 M(+59.7%)
$736.47 M(+0.0%)
Sep 2014
-
$4.79 M(-6.7%)
$736.46 M(-0.8%)
Jun 2014
-
$5.14 M(-99.3%)
$742.75 M(+0.2%)
DateAnnualQuarterlyTTM
Mar 2014
-
$718.88 M(+9297.1%)
$741.59 M(+269.1%)
Dec 2013
$200.93 M(+115.1%)
$7.65 M(-31.0%)
$200.93 M(+3.4%)
Sep 2013
-
$11.08 M(+178.4%)
$194.24 M(+3.5%)
Jun 2013
-
$3.98 M(-97.8%)
$187.66 M(+1.8%)
Mar 2013
-
$178.21 M(>+9900.0%)
$184.30 M(+97.3%)
Dec 2012
$93.41 M(>+9900.0%)
$966.00 K(-78.5%)
$93.41 M(+0.8%)
Sep 2012
-
$4.50 M(+616.4%)
$92.71 M(+5.1%)
Jun 2012
-
$628.00 K(-99.3%)
$88.21 M(+0.2%)
Mar 2012
-
$87.32 M(>+9900.0%)
$88.05 M(>+9900.0%)
Dec 2011
$738.00 K(-79.9%)
$267.00 K(>+9900.0%)
$738.00 K(-26.1%)
Sep 2011
-
$0.00(-100.0%)
$998.00 K(-5.0%)
Jun 2011
-
$462.00 K(+5033.3%)
$1.05 M(-66.4%)
Mar 2011
-
$9000.00(-98.3%)
$3.13 M(-14.6%)
Dec 2010
$3.66 M(+4.4%)
$527.00 K(+894.3%)
$3.66 M(-2.9%)
Sep 2010
-
$53.00 K(-97.9%)
$3.77 M(-15.8%)
Jun 2010
-
$2.54 M(+368.8%)
$4.48 M(+16.7%)
Mar 2010
-
$542.00 K(-14.6%)
$3.84 M(+9.5%)
Dec 2009
$3.51 M(+11.2%)
$635.00 K(-16.8%)
$3.51 M(-675.2%)
Sep 2009
-
$763.00 K(-59.9%)
-$610.00 K(-360.7%)
Jun 2009
-
$1.90 M(+805.2%)
$234.00 K(-93.9%)
Mar 2009
-
$210.00 K(-106.0%)
$3.84 M(+21.6%)
Dec 2008
$3.15 M(-94.6%)
-$3.48 M(-316.8%)
$3.15 M(-57.3%)
Sep 2008
-
$1.61 M(-70.8%)
$7.39 M(-88.4%)
Jun 2008
-
$5.50 M(-1266.1%)
$63.76 M(+8.9%)
Mar 2008
-
-$472.00 K(-162.5%)
$58.56 M(-0.1%)
Dec 2007
$58.63 M(-64.8%)
$755.00 K(-98.7%)
$58.63 M(-63.3%)
Sep 2007
-
$57.97 M(>+9900.0%)
$159.58 M(+56.1%)
Jun 2007
-
$303.00 K(-176.5%)
$102.22 M(-1.5%)
Mar 2007
-
-$396.00 K(-100.4%)
$103.75 M(-37.7%)
Dec 2006
$166.63 M(+216.7%)
$101.70 M(>+9900.0%)
$166.63 M(+42.3%)
Sep 2006
-
$617.00 K(-66.4%)
$117.09 M(+0.8%)
Jun 2006
-
$1.84 M(-97.1%)
$116.13 M(+1.4%)
Mar 2006
-
$62.48 M(+19.8%)
$114.50 M(+117.6%)
Dec 2005
$52.62 M(+3.2%)
$52.15 M(<-9900.0%)
$52.62 M(+777.8%)
Sep 2005
-
-$343.00 K(-265.7%)
$5.99 M(-20.2%)
Jun 2005
-
$207.00 K(-65.6%)
$7.51 M(-82.4%)
Mar 2005
-
$602.00 K(-89.1%)
$42.59 M(-16.5%)
Dec 2004
$50.98 M(+115.0%)
$5.53 M(+369.7%)
$50.98 M(+12.2%)
Sep 2004
-
$1.18 M(-96.7%)
$45.45 M(+2.7%)
Jun 2004
-
$35.28 M(+292.3%)
$44.27 M(+392.3%)
Mar 2004
-
$8.99 M
$8.99 M
Dec 2003
$23.71 M(+36.9%)
-
-
Dec 2002
$17.32 M
-
-

FAQ

  • What is Alnylam Pharmaceuticals annual cash flow from financing activities?
  • What is the all time high annual CFF for Alnylam Pharmaceuticals?
  • What is Alnylam Pharmaceuticals annual CFF year-on-year change?
  • What is Alnylam Pharmaceuticals quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Alnylam Pharmaceuticals?
  • What is Alnylam Pharmaceuticals quarterly CFF year-on-year change?
  • What is Alnylam Pharmaceuticals TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Alnylam Pharmaceuticals?
  • What is Alnylam Pharmaceuticals TTM CFF year-on-year change?

What is Alnylam Pharmaceuticals annual cash flow from financing activities?

The current annual CFF of ALNY is $294.16 M

What is the all time high annual CFF for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals all-time high annual cash flow from financing activities is $1.25 B

What is Alnylam Pharmaceuticals annual CFF year-on-year change?

Over the past year, ALNY annual cash flow from financing activities has changed by +$122.03 M (+70.89%)

What is Alnylam Pharmaceuticals quarterly cash flow from financing activities?

The current quarterly CFF of ALNY is $31.00 M

What is the all time high quarterly CFF for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals all-time high quarterly cash flow from financing activities is $718.88 M

What is Alnylam Pharmaceuticals quarterly CFF year-on-year change?

Over the past year, ALNY quarterly cash flow from financing activities has changed by -$8.23 M (-20.98%)

What is Alnylam Pharmaceuticals TTM cash flow from financing activities?

The current TTM CFF of ALNY is $294.16 M

What is the all time high TTM CFF for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals all-time high TTM cash flow from financing activities is $1.25 B

What is Alnylam Pharmaceuticals TTM CFF year-on-year change?

Over the past year, ALNY TTM cash flow from financing activities has changed by +$122.03 M (+70.89%)